RAMB Julho/Agosto 2015

ernardi

380

ssoc

ras

2015; 61(4):375-380

Baena CP, Chowdhury R, Schio NA, Sabbag Jr AE, Guarita-Souza LC,

Olandoski M, et al. Ischaemic heart disease deaths in Brazil: current trends,

regional disparities and future projections. Heart. 2013; 99(18):1359-64.

Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al.

Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.

N Engl J Med. 2007; 356(23):2388-98.

4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of

potentially modifiable risk factors associated with myocardial infarction in

52 countries (the INTERHEART study): case-control study. Lancet. 2004;

364(9438):937-52.

5. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al.

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22

countries (the INTERSTROKE study): a case-control study. Lancet. 2010;

376(9735):112-23.

Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker

P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and

blood pressure: a meta-analysis of individual data from 61 prospective studies

with 55,000 vascular deaths. Lancet. 2007; 370(9602):1829-39.

7. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell

L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive

lowering of LDL cholesterol: a meta-analysis of data from 170,000

participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81.

8. O’Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention:

ameta-analysis involving 121,000 patients. American J Med. 2008; 121(1):24-33.

9. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson

J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol

with statin therapy in people at low risk of vascular disease: meta-analysis of

individual data from 27 randomised trials. Lancet. 2012; 380(9841):581-90.

10. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell

L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy

in 18,686 people with diabetes in 14 randomised trials of statins: a meta-

analysis. Lancet. 2008; 371(9607):117-25.

11.

National Center for Health S. Health, United States. Health, United States,

2010: With Special Feature on Death and Dying. Hyattsville (MD): National

Center for Health Statistics (US), 2011.

12.

Pencina MJ, Navar-Boggan AM, D’Agostino Sr RB, Williams K, Neely B,

Sniderman AD, et al. Application of new cholesterol guidelines to a

population-based sample. N Engl J Med. 2014; 370:1422-31.

13.

Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et

al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce

atherosclerotic cardiovascular risk in adults: a report of the American College

of Cardiology/American Heart Association Task Force on Practice Guidelines.

J Am Coll Cardiol. 2014; 63(25 Pt B):2889-934.

14.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al.

Statins and risk of incident diabetes: a collaborative meta-analysis of

randomised statin trials. Lancet. 2010; 375(9716):735-42.

15.

Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk

of incident diabetes with intensive-dose compared with moderate-dose

statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556-64.

16. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM.

Risk of incident diabetes among patients treated with statins: population

based study. BMJ. 2013; 346:f2610.

17.

Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et

al. Meta-analysis of impact of different types and doses of statins on new-

onset diabetes mellitus. American J Cardiol. 2013; 111(8):1123-30.

18. Danaei G, Garcia Rodriguez LA, Fernandez Cantero O, Hernan MA. Statins

and risk of diabetes: an analysis of electronic medical records to evaluate

possible bias due to differential survival. Diabetes Care. 2013; 36(5):1236-40.

19.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ,

et al. Rosuvastatin to prevent vascular events in men and women with

elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207.

20.

Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin

and the development of diabetes mellitus: evidence for a protective treatment

effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;

103(3):357-62.

21.

Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary

prevention of cardiovascular events with long-term pravastatin in patients

with diabetes or impaired fasting glucose: results from the LIPID trial.

Diabetes Care. 2003; 26(10):2713-21.

22. Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the

development of new-onset type 2 diabetes: a meta-analysis of randomized

controlled trials. Curr Med Res Opin. 2008; 24(5):1359-62.

23.

Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah

T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and

bodyweight: evidence from genetic analysis and randomised trials. Lancet.

2015; 385(9965):351-61.

24.

Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular

benefits and diabetes risks of statin therapy in primary prevention: an

analysis from the JUPITER trial. Lancet. 2012; 380(9841):565-71.

25. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun C-C, et al.

Predictors of new-onset diabetes in patients treated with atorvastatin: results

from3 large randomized clinical trials. J AmColl Cardiol. 2011; 57(14):1535-45.

26.

Sattar N, Taskinen MR. Statins are diabetogenic--myth or reality? Atheroscler

Suppl. 2012; 13(1):1-10.

27.

Kawai Y, Sato-Ishida R, Motoyama A, Kajinami K. Place of pitavastatin in

the statin armamentarium: promising evidence for a role in diabetes mellitus.

Drug Des Devel Ther. 2011; 5:283-97.

28. Corrao G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, et al.

Statins and the risk of diabetes: evidence from a large population-based

cohort study. Diabetes Care. 2014; 37(8):2225-32.

29.

Ko DT, Wijeysundera HC, Jackevicius CA, Yousef A, Wang J, Tu JV. Diabetes

mellitus and cardiovascular events in older patients with myocardial

infarction prescribed intensive-dose and moderate-dose statins. Circ

Cardiovasc Qual Outcomes. 2013; 6(3):315-22.

30. Altunbas H, Balci MK, Karayalcin U. No effect of simvastatin treatment on

insulin sensitivity in patients with primary hypercholesterolemia. Endocr

Res. 2003; 29(3):265-75.

31.

Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, et al. Early

vascular and metabolic effects of rosuvastatin compared with simvastatin

in patients with type 2 diabetes. Atherosclerosis. 2010; 210(1):199-201.

32.

Paniagua JA, Lopez-Miranda J, Escribano A, Berral FJ, Marin C, Bravo D, et

al. Cerivastatin improves insulin sensitivity and insulin secretion in early-

state obese type 2 diabetes. Diabetes. 2002; 51(8):2596-603.

33.

Szendroedi J, Anderwald C, Krssak M, Bayerle-Eder M, Esterbauer H, Pfeiler

G, et al. Effects of high-dose simvastatin therapy on glucose metabolism

and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes

Care. 2009; 32(2):209-14.

34.

ter Avest E, Abbink EJ, de Graaf J, Tack CJ, Stalenhoef AF. Effect of

rosuvastatin on insulin sensitivity in patients with familial combined

hyperlipidaemia. Eur J Clin Invest. 2005; 35(9):558-64.

35.

Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on

insulin sensitivity in non-diabetics: a systematic review and meta-analysis.

Diabetes Res Clin Pract. 2010; 87(1):98-107.

36.

Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis

H, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs.

simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract.

2011; 65(11):1141-8.

37. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not

pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion

due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol.

1999; 126(5):1205-13.

38.

Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, et al.

Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin

secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb. 2006;

13(6):329-35.

39.

Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of

recent evidence. Curr Opin Lipidol. 2011; 22(6):460-6.

40.

Mansi I, Frei CR, Wang CP, Mortensen EM. Statins and New-Onset Diabetes

Mellitus and Diabetic Complications: A Retrospective Cohort Study of US

Healthy Adults. J Gen Intern Med. 2015. [Epub ahead of print]